Fewer than 10% of individuals that would benefit from GLP-1 drugs like Wegovy are able to get them, states the World Health Organization as it publishes its first recommendations on the medications.
Considering in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is urging increased and just access to these injectable treatments.
Based on estimates, over two billion could be living with obesity by 2030 without intervention.
"The latest guidelines affirms that obesity is a chronic disease that can be treated with holistic and lifelong care," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and logistical bottlenecks are key obstacles to widespread access to the treatments that can aid individuals in losing significant body mass, notes the organization.
Skinny Jab Supply Crisis
Despite the present most optimistic outlook, the production of GLP-1 therapies would only suffice for approximately 100 million people – fewer than 10% of eligible patients, per the WHO.
The guideline urges nations and manufacturers to widen access, via strategies including patent sharing.
Exclusive production rights on a key compound – the core ingredient of Novo Nordisk's Wegovy – is set to lapse in several nations in 2026.
The Way Weight-Loss Injections Work
The injections imitate a biological compound to delay gastric emptying, suppress the appetite and boost feelings of fullness so users consume fewer calories.
Individuals typically start to lose weight after several weeks of commencing the regular doses.
Evidence indicates people may put most of the weight back on after a year of discontinuing the drug, when their typical appetite come back.
Being overweight or obese elevates your likelihood for developing medical conditions, including type 2 diabetes, heart disease, brain attack, and some cancers.
Obesity concerns people in every country and was responsible for 3.7 million fatalities worldwide in 2024, as per the health agency.
